Short-term Safety and Efficacy of Intravitreal Bavacizumab Injection.
10.3341/jkos.2009.50.2.219
- Author:
Su Jin KIM
1
;
Young Min PARK
;
Seung Uk LEE
;
Ji Eun LEE
;
Boo Sup OUM
Author Information
1. Department of Ophthalmology, College of Medicine, Pusan National University, Pusan, Korea. jlee@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
Bevacizumab;
Efficacy;
Safety
- MeSH:
Antibodies, Monoclonal, Humanized;
Endophthalmitis;
Eye;
Glaucoma;
Humans;
Hypertension;
Macular Degeneration;
Macular Edema;
Medical Records;
Myocardial Infarction;
Retinal Detachment;
Retinaldehyde;
Tomography, Optical Coherence;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2009;50(2):219-226
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the short-term safety and efficacy of intravitreal bevacizumab (Avastin(R)) injection for various conditions. METHODS: The medical records of 257 eyes of 251 patients who underwent intravitreal bevacizumab injections were reviewed. Central retinal thickness on optical coherence tomography and visual acuity before injections, at 1 week, 1 month, 2 months and 3 months after injections were analyzed. RESULTS: The patients included age-related macular degeneration (89 eyes), diabetic macular edema (67 eyes) and retinal vascular occlusion (57 eyes). The number of injections was twice in 82 eyes, 3 times in 23 eyes and 4 times in 2 eyes. In total, 391 injections were performed. Best corrected visual acuity increased significantly at 3 months (p=0.033) and central retinal thickness decreased by 1 month and was maintained until 3 months after the first injection (p<0.001). No serious drug-related ocular or systemic adverse incidents including endophthalmitis, glaucoma, retinal detachment, hypertension or myocardial infarction were identified. CONCLUSIONS: The intravitreal bevacizumab injection was safe and efficient for macular edema in this short-term study.
